720 related articles for article (PubMed ID: 24553136)
1. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Paolino M; Choidas A; Wallner S; Pranjic B; Uribesalgo I; Loeser S; Jamieson AM; Langdon WY; Ikeda F; Fededa JP; Cronin SJ; Nitsch R; Schultz-Fademrecht C; Eickhoff J; Menninger S; Unger A; Torka R; Gruber T; Hinterleitner R; Baier G; Wolf D; Ullrich A; Klebl BM; Penninger JM
Nature; 2014 Mar; 507(7493):508-12. PubMed ID: 24553136
[TBL] [Abstract][Full Text] [Related]
2. TAM receptors attenuate murine NK-cell responses via E3 ubiquitin ligase Cbl-b.
Chirino LM; Kumar S; Okumura M; Sterner DE; Mattern M; Butt TR; Kambayashi T
Eur J Immunol; 2020 Jan; 50(1):48-55. PubMed ID: 31531847
[TBL] [Abstract][Full Text] [Related]
3. Cancer: Unleashing NK cell anti-metastatic activity.
Flemming A
Nat Rev Drug Discov; 2014 Apr; 13(4):257. PubMed ID: 24687061
[No Abstract] [Full Text] [Related]
4. Signalling: loss of Cbl-b unleashes anti-metastatic natural killer cells.
Lokody I
Nat Rev Cancer; 2014 Apr; 14(4):218. PubMed ID: 24622519
[No Abstract] [Full Text] [Related]
5. Immunotherapy: killing with natural killers, naturally.
Villanueva MT
Nat Rev Clin Oncol; 2014 Apr; 11(4):180. PubMed ID: 24590132
[No Abstract] [Full Text] [Related]
6. E3 ubiquitin ligase Cbl-b regulates Pten via Nedd4 in T cells independently of its ubiquitin ligase activity.
Guo H; Qiao G; Ying H; Li Z; Zhao Y; Liang Y; Yang L; Lipkowitz S; Penninger JM; Langdon WY; Zhang J
Cell Rep; 2012 May; 1(5):472-82. PubMed ID: 22763434
[TBL] [Abstract][Full Text] [Related]
7. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
8. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
Paolino M; Thien CB; Gruber T; Hinterleitner R; Baier G; Langdon WY; Penninger JM
J Immunol; 2011 Feb; 186(4):2138-47. PubMed ID: 21248250
[TBL] [Abstract][Full Text] [Related]
9. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
10. The role of the e3 ligase cbl-B in murine dendritic cells.
Wallner S; Lutz-Nicoladoni C; Tripp CH; Gastl G; Baier G; Penninger JM; Stoitzner P; Wolf D
PLoS One; 2013; 8(6):e65178. PubMed ID: 23762309
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1.
Kojo S; Elly C; Harada Y; Langdon WY; Kronenberg M; Liu YC
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17847-51. PubMed ID: 19815501
[TBL] [Abstract][Full Text] [Related]
12. SLAP2 Adaptor Binding Disrupts c-CBL Autoinhibition to Activate Ubiquitin Ligase Function.
Wybenga-Groot LE; Tench AJ; Simpson CD; Germain JS; Raught B; Moran MF; McGlade CJ
J Mol Biol; 2021 Apr; 433(8):166880. PubMed ID: 33617900
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.
Qiao G; Li Z; Molinero L; Alegre ML; Ying H; Sun Z; Penninger JM; Zhang J
Mol Cell Biol; 2008 Apr; 28(7):2470-80. PubMed ID: 18227156
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.
Qiao G; Lei M; Li Z; Sun Y; Minto A; Fu YX; Ying H; Quigg RJ; Zhang J
J Immunol; 2007 Oct; 179(7):4473-9. PubMed ID: 17878343
[TBL] [Abstract][Full Text] [Related]
15. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
[TBL] [Abstract][Full Text] [Related]
16.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
17. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.
Gioia R; Trégoat C; Dumas PY; Lagarde V; Prouzet-Mauléon V; Desplat V; Sirvent A; Praloran V; Lippert E; Villacreces A; Leconet W; Robert B; Vigon I; Roche S; Mahon FX; Pasquet JM
J Pathol; 2015 Sep; 237(1):14-24. PubMed ID: 25965880
[TBL] [Abstract][Full Text] [Related]
18. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase.
Kimani SG; Kumar S; Davra V; Chang YJ; Kasikara C; Geng K; Tsou WI; Wang S; Hoque M; Boháč A; Lewis-Antes A; De Lorenzo MS; Kotenko SV; Birge RB
Cell Commun Signal; 2016 Sep; 14(1):19. PubMed ID: 27595981
[TBL] [Abstract][Full Text] [Related]
19. PKC-theta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation.
Gruber T; Hermann-Kleiter N; Hinterleitner R; Fresser F; Schneider R; Gastl G; Penninger JM; Baier G
Sci Signal; 2009 Jun; 2(76):ra30. PubMed ID: 19549985
[TBL] [Abstract][Full Text] [Related]
20. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo.
Wohlfert EA; Gorelik L; Mittler R; Flavell RA; Clark RB
J Immunol; 2006 Feb; 176(3):1316-20. PubMed ID: 16424156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
